☰

Charles B. Kemmler, Ph.D. - Publications

Affiliations: 
2011 University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 
Area:
Immunology, Oncology, Cell Biology
Tree Info Grants Similar researchers PubMed Report error

6 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, et al. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. Plos One. 9: e101904. PMID 25051027 DOI: 10.1371/Journal.Pone.0101904  0.617
2013 Buhrman JD, Jordan KR, U'ren L, Sprague J, Kemmler CB, Slansky JE. Augmenting antitumor T-cell responses to mimotope vaccination by boosting with native tumor antigens. Cancer Research. 73: 74-85. PMID 23161490 DOI: 10.1158/0008-5472.Can-12-1005  0.59
2011 Kemmler CB, Clambey ET, Kedl RM, Slansky JE. Elevated tumor-associated antigen expression suppresses variant peptide vaccine responses. Journal of Immunology (Baltimore, Md. : 1950). 187: 4431-9. PMID 21940675 DOI: 10.4049/Jimmunol.1101555  0.777
2010 Jordan KR, McMahan RH, Kemmler CB, Kappler JW, Slansky JE. Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proceedings of the National Academy of Sciences of the United States of America. 107: 4652-7. PMID 20133772 DOI: 10.1073/Pnas.0914879107  0.678
2008 McWilliams JA, Sullivan RT, Jordan KR, McMahan RH, Kemmler CB, McDuffie M, Slansky JE. Age-dependent tolerance to an endogenous tumor-associated antigen. Vaccine. 26: 1863-73. PMID 18329760 DOI: 10.1016/J.Vaccine.2008.01.052  0.649
2007 Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 25: 1452-63. PMID 17098335 DOI: 10.1016/J.Vaccine.2006.10.035  0.46
Show low-probability matches.